Developer docs
API playgroundTry for free, no card

Search company profiles

Checkmate Pharmaceuticals

Full company profile

uuid0006flz

Namestring
Checkmate Pharmaceuticals
Legal namestring
Checkmate Pharmaceuticals
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2015 and based in Cambridge, Massachusetts, that develops intratumoral cancer immunotherapies designed to be administered directly into tumors and used in combination with immune checkpoint inhibitors such as anti-PD-1 antibodies. The company's lead clinical candidate, vidutolimod (CMP-CPS-001), is a Toll-like receptor 9 (TLR9) agonist intended to convert "cold" tumor microenvironments into immune-active ones, thereby enhancing the activity of systemic checkpoint blockade across multiple solid tumor indications. The pipeline strategy is explicitly combination-focused: vidutolimod is positioned not as a standalone agent but as a complementary modality to established PD-1/PD-L1 inhibitors, targeting indications such as melanoma, non-small cell lung cancer, and other solid tumors in investigator- and company-sponsored clinical trials.

The company is pre-revenue, with no approved products and no commercial sales infrastructure; its only monetization pathway is via future out-licensing, partnership milestones, or royalty arrangements with large pharma partners following clinical proof-of-concept. Between 2015 and 2020 Checkmate raised approximately $170 million across multiple private rounds and an initial public offering on NASDAQ (ticker CMPI), backed by specialist life-sciences investors including F-Prime, venBio Partners, Sofinnova Investments, Decheng Capital, Longitude Capital, and Novo Holdings. Leadership is concentrated in a small executive team of 11-50 employees, anchored by founder and Chief Scientific Officer Art Krieg, an established immunology and oligonucleotide therapeutics researcher. The company is currently delisted from NASDAQ, with no post-2020 operational, clinical, or financial disclosures available in the input data.

Short descriptiontext

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company developing vidutolimod, an intratumoral TLR9 agonist immunotherapy, intended for use in combination with checkpoint inhibitors across multiple solid tumor indications. The company is pre-revenue and is currently delisted from public markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cancer immunotherapy, intratumoral therapy, oncology drug development, clinical stage biopharmaceutical, immune checkpoint inhibitors
Industry1 code
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy
No data
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company developing intratumoral cancer immunotherapies, with research focus on combination strategies that pair immune checkpoint inhibitors with innate immunity-targeting agents to treat solid tumors.

Differentiator
Functional benefit
Problem solved
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Checkmate Pharmaceuticals

Cancer Immunotherapycheckmatepharma.com

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company developing vidutolimod, an intratumoral TLR9 agonist immunotherapy, intended for use in combination with checkpoint inhibitors across multiple solid tumor indications. The company is pre-revenue and is currently delisted from public markets.

What Checkmate Pharmaceuticals does

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2015 and based in Cambridge, Massachusetts, that develops intratumoral cancer immunotherapies designed to be administered directly into tumors and used in combination with immune checkpoint inhibitors such as anti-PD-1 antibodies. The company's lead clinical candidate, vidutolimod (CMP-CPS-001), is a Toll-like receptor 9 (TLR9) agonist intended to convert "cold" tumor microenvironments into immune-active ones, thereby enhancing the activity of systemic checkpoint blockade across multiple solid tumor indications. The pipeline strategy is explicitly combination-focused: vidutolimod is positioned not as a standalone agent but as a complementary modality to established PD-1/PD-L1 inhibitors, targeting indications such as melanoma, non-small cell lung cancer, and other solid tumors in investigator- and company-sponsored clinical trials.

The company is pre-revenue, with no approved products and no commercial sales infrastructure; its only monetization pathway is via future out-licensing, partnership milestones, or royalty arrangements with large pharma partners following clinical proof-of-concept. Between 2015 and 2020 Checkmate raised approximately $170 million across multiple private rounds and an initial public offering on NASDAQ (ticker CMPI), backed by specialist life-sciences investors including F-Prime, venBio Partners, Sofinnova Investments, Decheng Capital, Longitude Capital, and Novo Holdings. Leadership is concentrated in a small executive team of 11-50 employees, anchored by founder and Chief Scientific Officer Art Krieg, an established immunology and oligonucleotide therapeutics researcher. The company is currently delisted from NASDAQ, with no post-2020 operational, clinical, or financial disclosures available in the input data.

Checkmate Pharmaceuticals firmographics

Firmographics
Name
Checkmate Pharmaceuticals
Legal name
Checkmate Pharmaceuticals
Website
https://checkmatepharma.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company developing vidutolimod, an intratumoral TLR9 agonist immunotherapy, intended for use in combination with checkpoint inhibitors across multiple solid tumor indications. The company is pre-revenue and is currently delisted from public markets.
Ownership category
akta.pro rank

Checkmate Pharmaceuticals industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Cancer immunotherapy
  • Intratumoral therapy
  • Oncology drug development
  • Clinical stage biopharmaceutical
  • Immune checkpoint inhibitors

Where Checkmate Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Checkmate Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Checkmate Pharmaceuticals product offering

Product offering

Core offering

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company developing intratumoral cancer immunotherapies, with research focus on combination strategies that pair immune checkpoint inhibitors with innate immunity-targeting agents to treat solid tumors.

Differentiator

Problem solved

Functional benefit

Companies that use Checkmate Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

Checkmate Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Checkmate Pharmaceuticals partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights4 records

Checkmate Pharmaceuticals competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Checkmate Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Checkmate Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

Checkmate Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Checkmate Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Checkmate Pharmaceuticals

What does Checkmate Pharmaceuticals do?

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company developing intratumoral cancer immunotherapies, with research focus on combination strategies that pair immune checkpoint inhibitors with innate immunity-targeting agents to treat solid tumors.

Is Checkmate Pharmaceuticals a public or private company?

Checkmate Pharmaceuticals is a private company. It is classified as unknown and is currently operating.

When was Checkmate Pharmaceuticals founded?

Checkmate Pharmaceuticals was founded in 2015. It employs 1 to 10 people.

Where is Checkmate Pharmaceuticals based?

Checkmate Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.

Does Checkmate Pharmaceuticals have an API?

No public API is recorded for Checkmate Pharmaceuticals.

What industry is Checkmate Pharmaceuticals in?

Checkmate Pharmaceuticals's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comIntratumoral Cancer Therapies Market: Expanding Revenue Landscape to 2034 - DelveInsight | Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharma, Checkmate Pharma, ReplimuneThe article reports on the expanding market for intratumoral cancer therapies through 2034, highlighting key companies involved, recent clinical developments, and market trends across major regions.KriyatherapeuticsKriya Appoints Katherine Eade as Chief Legal OfficerKriya Therapeutics has appointed Katherine Eade as its new Chief Legal Officer to oversee legal strategy, intellectual property, and compliance across its gene therapy operations. Eade brings over two decades of experience in biopharma legal leadership, including previous roles at Checkmate Pharmaceuticals and Harvard Bioscience.PR NewswireSkin Cancer Drugs Global Market Research Report 2023 with Focus on vismodegib (Erivedge) and sonidegib (Odomzo) - Forecasts to 2027 and 2032ResearchAndMarkets.com published a global market research report on skin cancer drugs, projecting the market to grow from $3.03 billion in 2022 to $5.23 billion in 2027 at a combined CAGR of approximately 12%. The report identifies key market drivers including rising skin cancer prevalence and strategic alliances among pharmaceutical companies, while noting restraints such as competition from targeted therapies. It also mentions a specific acquisition: Regeneron acquired Checkmate Pharmaceuticals for $250 million in April 2022 to expand its immuno-oncology research.PR NewswireRegeneron Reports Second Quarter 2022 Financial and Operating ResultsRegeneron Pharmaceuticals reported a 44% year-over-year decline in second-quarter revenues to $2.86 billion, primarily due to the cessation of REGEN-COV sales, though core revenue excluding that product grew by 20%. The company strengthened its oncology portfolio by acquiring global rights to Libtayo from Sanofi for a $900 million upfront payment and purchased Checkmate Pharmaceuticals for approximately $250 million.GlobeNewswireKuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone PaymentKuros Biosciences received a $5 million milestone payment from Checkmate Pharmaceuticals upon its acquisition by Regeneron, with $2.5 million going to XOMA under a 2021 royalty purchase agreement. The payment stems from a 2015 license agreement for vidutolimod, which Checkmate is developing in tumor trials.PR NewswireRegeneron Completes Acquisition of Checkmate PharmaceuticalsRegeneron completed its acquisition of Checkmate Pharmaceuticals, paying $10.50 per share for 18,471,314 shares tendered, representing about 83.8% of outstanding shares. The deal adds Checkmate's vidutolimod, a TLR9 agonist, to Regeneron's immuno-oncology portfolio. Regeneron expects to expense the acquired in-process R&D in Q2 2022.PR NewswireSHAREHOLDER ALERT: Weiss Law Reminds FSI, NTUS, ACC, and CMPI Shareholders About Its Ongoing InvestigationsWeiss Law, a law firm, announced ongoing investigations into four separate proposed acquisitions for potential breaches of fiduciary duty by target company boards. The four deals under scrutiny are: the proposed merger of Flexible Solutions International Inc. with Lygos, Inc. ($160 million convertible notes); the acquisition of Natus Medical Incorporated by an ArchiMed affiliate ($33.50 per share); the acquisition of American Campus Communities, Inc. by Blackstone Inc. ($65.47 per share); and the acquisition of Checkmate Pharmaceuticals, Inc. by Regeneron Pharmaceuticals via tender offer ($10.50 per share). Shareholders of the respective companies are encouraged to contact Weiss Law to discuss their rights or interests.PR NewswireRegeneron Reports First Quarter 2022 Financial and Operating ResultsRegeneron Pharmaceuticals reported Q1 2022 revenues of $2.97 billion, a 17% increase year-over-year, with non-GAAP diluted EPS of $11.49, driven by strong growth in EYLEA (up 13% to $1.52 billion U.S. net sales) and Dupixent (up 43% to $1.81 billion global net sales). The company also announced the pending acquisition of Checkmate Pharmaceuticals for approximately $250 million and received FDA priority review designations for Dupixent in atopic dermatitis and eosinophilic esophagitis, while REGEN-COV faced a three-month FDA review extension due to Omicron variant concerns.PR NewswireSHAREHOLDER ALERT: Weiss Law Reminds FSI, NTUS, ACC, and CMPI Shareholders About Its Ongoing InvestigationsWeiss Law has initiated investigations into the boards of Flexible Solutions International, Natus Medical, American Campus Communities, and Checkmate Pharmaceuticals for potential breaches of fiduciary duty related to their respective proposed mergers or acquisitions. The article outlines specific transaction details for each company, including share prices and acquiring entities such as Lygos, ArchiMed, Blackstone, and Regeneron.